These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10776986)

  • 21. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer.
    Uitterhoeve AL; Belderbos JS; Koolen MG; van der Vaart PJ; Rodrigus PT; Benraadt J; Koning CC; González González D; Bartelink H
    Eur J Cancer; 2000 Mar; 36(5):592-600. PubMed ID: 10738123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
    Curran WJ; Cox JD; Azarnia N; Byhardt RW; Shin KH; Emani B; Phillips TL; Selim H; Herskovic A; Mohiuddin M
    Cancer; 1991 Aug; 68(3):509-16. PubMed ID: 1648432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
    Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
    Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; De Jaeger K; Heemsbergen WD; Seppenwoolde Y; Baas P; Boersma LJ; Lebesque JV
    Radiother Oncol; 2003 Feb; 66(2):119-26. PubMed ID: 12648783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer.
    Byhardt RW
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1513-25. PubMed ID: 7635796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
    Johnstone DW; Byhardt RW; Ettinger D; Scott CB
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
    Murray KJ; Scott C; Greenberg HM; Emami B; Seider M; Vora NL; Olson C; Whitton A; Movsas B; Curran W
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):571-4. PubMed ID: 9336134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
    Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
    Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
    Firat S; Byhardt RW; Gore E
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.
    Butler EB; Teh BS; Grant WH; Uhl BM; Kuppersmith RB; Chiu JK; Donovan DT; Woo SY
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):21-32. PubMed ID: 10477002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
    Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.